Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: HIV-1 Infection, H1N1, Influenza, Flu
Interventions: FluMist, Fluvirin, Fluzone; Biological
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 6 Months to 25 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions: LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 716 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Garden Grove, California • Lomita, California • DeLand, Florida + 6 more

Conditions: Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions: Influenza Vaccine Recipients; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hematologic Disorder
Interventions: Lenalidomide, Influenza Vaccine, Pneumovax Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: G-CSF, Decitabine, Venetoclax; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza A
Interventions: VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 129
States / cities: Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: mRNA-1018-H5, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more

Conditions: Influenza A, Influenza B
Interventions: Anti-Influenza Immune Plasma, Standard Care; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 35
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 22 more

Conditions: Influenza
Interventions: CAIV-T 10^7, CAIVT 10^5, Placebo, TIV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 2
States / cities: New Port Richey, Florida • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: HAI-05 Influenza Vaccine, Saline; Biological · Other
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Wichita, Kansas • Kansas City, Missouri

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: Influenza
Interventions: fluID Rapid Influenza Test, BinaxNOW® Influenza A & B; Device
Lead sponsor: Nanogen, Inc.; Industry
Eligibility: Not listed
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 2
States / cities: Shreveport, Louisiana • Milwaukee, Wisconsin

Conditions: Influenza
Interventions: Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more

Conditions: Influenza A Subtype H7N7 Infection
Interventions: Monovalent Influenza Subvirion Vaccine, H7N7; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Volunteers
Interventions: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein); Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) 2009 monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more

Conditions: Influenza, Human
Interventions: Elderberry Extract, Placebos; Drug
Lead sponsor: michael macknin; Other
Eligibility: 5 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions: artus Influenza A/B RT-PCR Test; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more

Search by objective public record fields.

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

H9 Priming Study in Healthy Adults

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Symphony IL-6 Study in Patients at Risk of Severe Sepsis

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

H5N1 Mix and Match With MF59

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza

T and B Cell Response to Avian Flu Vaccine

Collection and Testing of Respiratory Samples